Royal Bank Of Canada Exelixis, Inc. Transaction History

Royal Bank Of Canada

$471 Billion
Q3 2024

A detailed history of Royal Bank Of Canada transactions in Exelixis, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 620,269 shares of EXEL stock, worth $22.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

620,269

Previous 142,579 335.04%

Holding current value

$22.1 Million

Previous $3.2 Million 402.5%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$21.96 - $27.6 $10.5 Million - $13.2 Million	477,690 Added 335.04%	620,269 $16.1 Million
Q2 2024 Aug 14, 2024	SELL	$20.34 - $23.73 $5.6 Million - $6.54 Million	-275,506 Reduced 65.9%	142,579 $3.2 Million
Q1 2024 Nov 05, 2024	BUY	$20.17 - $23.93 $486,339 - $577,000	24,112 Added 16.91%	166,691 $3.96 Million
Q1 2024 May 15, 2024	BUY	$20.17 - $23.93 $4.97 Million - $5.89 Million	246,276 Added 143.34%	418,085 $9.92 Million
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $1.05 Million - $1.31 Million	54,322 Added 46.24%	171,809 $4.12 Million
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $319,643 - $381,759	16,788 Added 16.67%	117,487 $2.57 Million
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $957,740 - $1.08 Million	-52,710 Reduced 34.36%	100,699 $1.92 Million
Q1 2023 May 15, 2023	SELL	$16.3 - $19.41 $3.13 Million - $3.73 Million	-192,305 Reduced 55.63%	153,409 $2.98 Million
Q4 2022 Feb 14, 2023	SELL	$14.96 - $17.39 $479,004 - $556,810	-32,019 Reduced 8.48%	345,714 $5.55 Million
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $3.05 Million - $4.33 Million	-194,641 Reduced 34.01%	377,733 $5.92 Million
Q2 2022 Aug 15, 2022	BUY	$17.44 - $23.16 $3.94 Million - $5.23 Million	225,919 Added 65.21%	572,374 $11.9 Million
Q1 2022 May 16, 2022	BUY	$17.03 - $22.67 $695,624 - $926,001	40,847 Added 13.37%	346,455 $7.85 Million
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $978,215 - $1.35 Million	61,756 Added 25.33%	305,608 $5.59 Million
Q3 2021 Nov 15, 2021	SELL	$16.3 - $21.14 $1.06 Million - $1.37 Million	-64,909 Reduced 21.02%	243,852 $5.16 Million
Q2 2021 Aug 16, 2021	BUY	$17.95 - $25.56 $5.54 Million - $7.89 Million	308,761 New	308,761 $5.63 Million

Others Institutions Holding EXEL

# of Institutions

501

Shares Held

244M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Exelixis, Inc. Transaction History